Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Edema | 5 | 2022 | 25 | 2.100 |
Why?
|
| Diabetic Retinopathy | 5 | 2022 | 83 | 1.940 |
Why?
|
| Thermotolerance | 2 | 2024 | 5 | 1.750 |
Why?
|
| Visual Acuity | 7 | 2022 | 501 | 1.550 |
Why?
|
| Ranibizumab | 3 | 2019 | 11 | 1.160 |
Why?
|
| Climate Change | 3 | 2024 | 61 | 1.140 |
Why?
|
| Chiroptera | 2 | 2025 | 17 | 1.110 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2021 | 106 | 1.110 |
Why?
|
| Starvation | 2 | 2024 | 17 | 1.000 |
Why?
|
| Disease Reservoirs | 2 | 2025 | 35 | 0.950 |
Why?
|
| One Health | 1 | 2024 | 3 | 0.890 |
Why?
|
| Ophthalmic Solutions | 1 | 2024 | 84 | 0.830 |
Why?
|
| Anesthetics, Local | 1 | 2024 | 82 | 0.800 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2019 | 332 | 0.690 |
Why?
|
| Deep Brain Stimulation | 9 | 2021 | 402 | 0.680 |
Why?
|
| Anatomy | 1 | 2020 | 13 | 0.670 |
Why?
|
| Macular Degeneration | 1 | 2021 | 89 | 0.660 |
Why?
|
| Status Epilepticus | 3 | 2020 | 151 | 0.650 |
Why?
|
| Phenytoin | 2 | 2020 | 57 | 0.630 |
Why?
|
| Anticonvulsants | 3 | 2020 | 376 | 0.610 |
Why?
|
| Bees | 3 | 2024 | 51 | 0.600 |
Why?
|
| Valproic Acid | 2 | 2020 | 161 | 0.600 |
Why?
|
| Laser Coagulation | 1 | 2019 | 98 | 0.580 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 156 | 0.580 |
Why?
|
| Intravitreal Injections | 5 | 2022 | 39 | 0.540 |
Why?
|
| Dystonic Disorders | 4 | 2022 | 95 | 0.510 |
Why?
|
| Students, Medical | 1 | 2020 | 338 | 0.480 |
Why?
|
| Dystonia | 4 | 2022 | 162 | 0.460 |
Why?
|
| Hot Temperature | 2 | 2024 | 138 | 0.420 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 873 | 0.410 |
Why?
|
| Globus Pallidus | 4 | 2021 | 68 | 0.400 |
Why?
|
| Double-Blind Method | 7 | 2020 | 1602 | 0.320 |
Why?
|
| Tomography, Optical Coherence | 5 | 2019 | 441 | 0.280 |
Why?
|
| Informed Consent | 2 | 2024 | 338 | 0.260 |
Why?
|
| Humans | 35 | 2025 | 127455 | 0.260 |
Why?
|
| Child, Preschool | 13 | 2024 | 14462 | 0.230 |
Why?
|
| Disease Resistance | 1 | 2025 | 18 | 0.230 |
Why?
|
| Ecology | 1 | 2024 | 16 | 0.220 |
Why?
|
| Adolescent | 16 | 2024 | 20154 | 0.220 |
Why?
|
| Desiccation | 1 | 2024 | 43 | 0.220 |
Why?
|
| Virology | 1 | 2024 | 31 | 0.220 |
Why?
|
| Movement Disorders | 2 | 2022 | 221 | 0.220 |
Why?
|
| Propoxycaine | 1 | 2024 | 3 | 0.220 |
Why?
|
| Acclimatization | 1 | 2024 | 21 | 0.210 |
Why?
|
| Male | 24 | 2024 | 62861 | 0.210 |
Why?
|
| Immune Tolerance | 1 | 2025 | 154 | 0.210 |
Why?
|
| Animals | 5 | 2025 | 33205 | 0.210 |
Why?
|
| Female | 25 | 2024 | 68733 | 0.210 |
Why?
|
| Body Temperature Regulation | 1 | 2024 | 50 | 0.210 |
Why?
|
| Adaptive Immunity | 1 | 2024 | 99 | 0.210 |
Why?
|
| Single-Blind Method | 1 | 2024 | 236 | 0.200 |
Why?
|
| Congresses as Topic | 1 | 2024 | 175 | 0.200 |
Why?
|
| Treatment Outcome | 11 | 2021 | 12580 | 0.200 |
Why?
|
| Child | 16 | 2024 | 25296 | 0.200 |
Why?
|
| Adaptation, Physiological | 1 | 2025 | 258 | 0.200 |
Why?
|
| Cold-Shock Response | 1 | 2022 | 5 | 0.190 |
Why?
|
| Macula Lutea | 2 | 2019 | 25 | 0.190 |
Why?
|
| Bevacizumab | 2 | 2019 | 53 | 0.190 |
Why?
|
| Fluocinolone Acetonide | 1 | 2022 | 2 | 0.190 |
Why?
|
| Genome | 1 | 2025 | 465 | 0.190 |
Why?
|
| Myoclonus | 1 | 2022 | 32 | 0.180 |
Why?
|
| Drug Implants | 1 | 2022 | 41 | 0.180 |
Why?
|
| Breast Cancer Lymphedema | 1 | 2021 | 2 | 0.180 |
Why?
|
| Virus Diseases | 1 | 2024 | 271 | 0.180 |
Why?
|
| Temperature | 1 | 2022 | 288 | 0.180 |
Why?
|
| Lymphedema | 1 | 2021 | 18 | 0.180 |
Why?
|
| Emergency Medical Services | 2 | 2024 | 410 | 0.180 |
Why?
|
| Sports | 1 | 2022 | 61 | 0.170 |
Why?
|
| Lesch-Nyhan Syndrome | 1 | 2021 | 11 | 0.170 |
Why?
|
| Young Adult | 12 | 2021 | 9703 | 0.170 |
Why?
|
| Pantothenate Kinase-Associated Neurodegeneration | 1 | 2020 | 3 | 0.170 |
Why?
|
| Steroids | 1 | 2022 | 158 | 0.170 |
Why?
|
| Neurodegenerative Diseases | 1 | 2024 | 272 | 0.170 |
Why?
|
| Middle Aged | 11 | 2024 | 27867 | 0.170 |
Why?
|
| Cadaver | 1 | 2020 | 119 | 0.160 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2020 | 15 | 0.160 |
Why?
|
| Population Groups | 1 | 2020 | 28 | 0.160 |
Why?
|
| Adolescent Behavior | 1 | 2022 | 169 | 0.160 |
Why?
|
| Gonorrhea | 1 | 2020 | 42 | 0.160 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2020 | 156 | 0.160 |
Why?
|
| Glucocorticoids | 1 | 2022 | 337 | 0.150 |
Why?
|
| Retinal Perforations | 1 | 2019 | 5 | 0.150 |
Why?
|
| Vitreous Detachment | 1 | 2019 | 6 | 0.150 |
Why?
|
| Fibrinolysin | 1 | 2019 | 9 | 0.150 |
Why?
|
| Seizures | 1 | 2024 | 847 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2021 | 4987 | 0.150 |
Why?
|
| Visual Field Tests | 1 | 2019 | 50 | 0.150 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2018 | 19 | 0.140 |
Why?
|
| Educational Measurement | 1 | 2020 | 296 | 0.140 |
Why?
|
| Hyperkinesis | 1 | 2018 | 27 | 0.140 |
Why?
|
| Visual Fields | 1 | 2019 | 133 | 0.140 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 165 | 0.130 |
Why?
|
| Phenotype | 3 | 2022 | 4309 | 0.130 |
Why?
|
| Adult | 14 | 2024 | 30579 | 0.130 |
Why?
|
| Infant | 5 | 2024 | 12806 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 382 | 0.130 |
Why?
|
| Electric Power Supplies | 1 | 2017 | 19 | 0.130 |
Why?
|
| Parkinson Disease | 1 | 2024 | 701 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 155 | 0.120 |
Why?
|
| Cerebellar Ataxia | 1 | 2016 | 69 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 989 | 0.120 |
Why?
|
| Curriculum | 1 | 2020 | 767 | 0.110 |
Why?
|
| Albinism, Oculocutaneous | 1 | 2014 | 2 | 0.110 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2014 | 6 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2019 | 762 | 0.110 |
Why?
|
| Melanosis | 1 | 2014 | 9 | 0.110 |
Why?
|
| Nevus, Pigmented | 1 | 2014 | 30 | 0.110 |
Why?
|
| Efferent Pathways | 1 | 2014 | 7 | 0.110 |
Why?
|
| Diazepam | 1 | 2014 | 20 | 0.110 |
Why?
|
| Lorazepam | 1 | 2014 | 12 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 291 | 0.100 |
Why?
|
| Disclosure | 1 | 2014 | 149 | 0.100 |
Why?
|
| Time Factors | 3 | 2019 | 6169 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1601 | 0.090 |
Why?
|
| Exome | 1 | 2016 | 1064 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 900 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 440 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2022 | 6249 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1005 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5160 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1709 | 0.080 |
Why?
|
| Heart Failure | 1 | 2023 | 2288 | 0.080 |
Why?
|
| Neuronavigation | 1 | 2009 | 8 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 3720 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 1207 | 0.080 |
Why?
|
| Injections, Intramuscular | 1 | 2019 | 182 | 0.080 |
Why?
|
| Monitoring, Intraoperative | 1 | 2009 | 128 | 0.070 |
Why?
|
| Postoperative Hemorrhage | 1 | 2009 | 81 | 0.070 |
Why?
|
| Benzodiazepines | 1 | 2019 | 108 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2587 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2019 | 246 | 0.070 |
Why?
|
| Age Distribution | 1 | 2020 | 423 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2019 | 51 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 537 | 0.070 |
Why?
|
| Mutation | 2 | 2020 | 5948 | 0.070 |
Why?
|
| Hypotension | 1 | 2019 | 184 | 0.070 |
Why?
|
| Aged | 6 | 2020 | 20494 | 0.060 |
Why?
|
| Ubiquitins | 1 | 2025 | 37 | 0.060 |
Why?
|
| Pediatrics | 1 | 2014 | 1205 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6716 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2025 | 155 | 0.050 |
Why?
|
| Voice Training | 1 | 2024 | 6 | 0.050 |
Why?
|
| Species Specificity | 1 | 2025 | 516 | 0.050 |
Why?
|
| Midazolam | 1 | 2024 | 46 | 0.050 |
Why?
|
| Speech Therapy | 1 | 2024 | 14 | 0.050 |
Why?
|
| Dysarthria | 1 | 2024 | 24 | 0.050 |
Why?
|
| Valsartan | 1 | 2023 | 25 | 0.050 |
Why?
|
| Spain | 1 | 2023 | 60 | 0.050 |
Why?
|
| Public Opinion | 1 | 2024 | 58 | 0.050 |
Why?
|
| Age Factors | 1 | 2020 | 2814 | 0.050 |
Why?
|
| Tetrazoles | 1 | 2023 | 70 | 0.050 |
Why?
|
| Electrodes, Implanted | 2 | 2017 | 168 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2023 | 271 | 0.050 |
Why?
|
| Sarcoglycans | 1 | 2022 | 8 | 0.050 |
Why?
|
| Phylogeny | 1 | 2025 | 687 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2023 | 134 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2021 | 86 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2023 | 514 | 0.040 |
Why?
|
| Pantothenic Acid | 1 | 2020 | 6 | 0.040 |
Why?
|
| Laryngeal Diseases | 1 | 2020 | 28 | 0.040 |
Why?
|
| Saliva | 1 | 2021 | 130 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 145 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 131 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2020 | 43 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 92 | 0.040 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2020 | 46 | 0.040 |
Why?
|
| Plasma Kallikrein | 1 | 2019 | 1 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2020 | 66 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 511 | 0.040 |
Why?
|
| Vitreous Body | 1 | 2019 | 52 | 0.040 |
Why?
|
| Tissue Adhesions | 1 | 2019 | 30 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 362 | 0.040 |
Why?
|
| Cytokines | 1 | 2025 | 1326 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2021 | 476 | 0.040 |
Why?
|
| Fetal Growth Retardation | 1 | 2020 | 253 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 404 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 327 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 643 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2020 | 666 | 0.030 |
Why?
|
| Peroxisomal Multifunctional Protein-2 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Genomics | 1 | 2025 | 1548 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 97 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2020 | 890 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 680 | 0.030 |
Why?
|
| Exercise | 1 | 2022 | 845 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 611 | 0.030 |
Why?
|
| Third-Party Consent | 1 | 2014 | 27 | 0.030 |
Why?
|
| United States | 2 | 2024 | 11399 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2125 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 416 | 0.030 |
Why?
|
| Electrophysiological Phenomena | 1 | 2014 | 62 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2014 | 192 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3937 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1177 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 216 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 579 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3694 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2623 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2023 | 17076 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2014 | 395 | 0.020 |
Why?
|
| Differential Threshold | 1 | 2011 | 9 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2016 | 1011 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 2030 | 0.020 |
Why?
|
| Electromyography | 1 | 2011 | 138 | 0.020 |
Why?
|
| Reaction Time | 1 | 2011 | 156 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 562 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2011 | 105 | 0.020 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2011 | 77 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 170 | 0.020 |
Why?
|
| Research Design | 1 | 2014 | 694 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 429 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1422 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2009 | 90 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 120 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2011 | 283 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 2600 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2014 | 534 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 155 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 1892 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 240 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2009 | 260 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 954 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1438 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 384 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3269 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 3331 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2239 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 8368 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 2999 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 3051 | 0.010 |
Why?
|